Aug 2, 2021
Alain Maiore is the Co-Founder and CEO of Mnemo Therapeutics and has a mission to change the future of cell therapy. The Mnemo platform EnfiniT is an integrated drug discovery engine that combines T-cell engineering technologies with greater target identification to transform the body's immune response to overcome currently incurable diseases.
Mnemo has just raised $90 million in a Series A round, the largest round to date in France.
Alain says, "I think our job is to make sure that whatever technology we put together, everyone that is in need of having access to these drugs gets access to these drugs. So it is our responsibility to combine the technologies and medical development and the manufacturing of these drugs so that we can size the necessity of financial performance and shoulder reward with accessibility to every patient. That responsibility is increasingly important in the world that is opening to us."
@MnemoTx #MnemoTherapeutics #EnfiniT #Cancer #BloodCancer #CellTherapies #SolidTumors #DrugTargeting #TCells #Immunetherapies #epigenetics #CarTCells